Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2006

View Archived Issues

Millennium profiles recent highlights

Antiangiogenic effects of CTCE-9908 could explain its antimetastatic properties

Gilead Sciences: Q4 review

Update on H5N1 vaccine development projects

IND cleared for phase I study of Tramadol ER

BioSante awarded subcontract for recombinant Factor IX formulation work

New sugar-cholestanol with anticancer activity

Phase I/II study shows efficacy of cell therapy for nasopharyngeal carcinoma

Heparan sulfate mimetics tested against dengue virus and flaviviral encephalitis

Therapeutic potential of anthrax lethal toxin in Kaposi's sarcoma

Ono profiles progress of recent months

APEX-AMI pexelizumab trial set to conclude

TRO-19622 completes phase I trials

Solbec prepares for phase II trials of Coramsine

Akzo Nobel to create two independent companies

PBT-2 completes phase I program

European Commission approval for Novartis' acquisition of Chiron

Fortovase discontinued, Invirase preferred option

MC4 antagonist/serotonin transport inhibitor for stress-related anxiety and depression

New Abilify options now available

New treatments for hepatitis C described in recent Boehringer Ingelheim patent

Novel agents imparted for inflammatory disorders

Potent targeting of c-Fos enhances the antiosteogenic activity of new vitamin D analogues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...